ATE324459T1 - Ein herpes simplex virus komplex - Google Patents

Ein herpes simplex virus komplex

Info

Publication number
ATE324459T1
ATE324459T1 AT03739561T AT03739561T ATE324459T1 AT E324459 T1 ATE324459 T1 AT E324459T1 AT 03739561 T AT03739561 T AT 03739561T AT 03739561 T AT03739561 T AT 03739561T AT E324459 T1 ATE324459 T1 AT E324459T1
Authority
AT
Austria
Prior art keywords
hsv
herpes simplex
simplex virus
virus complex
avirulent
Prior art date
Application number
AT03739561T
Other languages
English (en)
Inventor
Susanne Moira Brown
Joe Conner
Original Assignee
Crusade Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9930910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324459(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crusade Lab Ltd filed Critical Crusade Lab Ltd
Application granted granted Critical
Publication of ATE324459T1 publication Critical patent/ATE324459T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03739561T 2002-02-12 2003-02-12 Ein herpes simplex virus komplex ATE324459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0203285.2A GB0203285D0 (en) 2002-02-12 2002-02-12 An herpes simplex virus complex

Publications (1)

Publication Number Publication Date
ATE324459T1 true ATE324459T1 (de) 2006-05-15

Family

ID=9930910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03739561T ATE324459T1 (de) 2002-02-12 2003-02-12 Ein herpes simplex virus komplex

Country Status (9)

Country Link
US (2) US7943144B2 (de)
EP (1) EP1474521B2 (de)
JP (1) JP4509572B2 (de)
AT (1) ATE324459T1 (de)
AU (1) AU2003245765B2 (de)
CA (1) CA2475604C (de)
DE (1) DE60304835T3 (de)
GB (2) GB0203285D0 (de)
WO (1) WO2003068809A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
EP1549339B1 (de) 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
US20090257982A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells
US20090257983A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells
US20090258879A1 (en) * 2008-04-12 2009-10-15 Scheiber Lane Bernard Method for treating cancer, rheumatoid arthritis and other medical diseases by utilizing modified virus virions to insert medications into targeted cells
NO2700405T3 (de) * 2008-05-29 2018-09-01
EP2694542A4 (de) * 2011-04-08 2014-10-08 Univ Duke Herpes-simplex-virus
WO2013106572A1 (en) * 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
EP2662117A1 (de) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus zur Behandlung von Leberkrebs
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US20190202886A1 (en) * 2016-05-11 2019-07-04 Ohio State Innovation Foundation ONCOLYTIC VIRUSES COMPRISING esRAGE AND METHODS OF TREATING CANCER
WO2017211945A1 (en) 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein h for propagation in a cell
EP3469070B1 (de) 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus mit modifiziertem glykoprotein b
KR20190015544A (ko) 2016-06-09 2019-02-13 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 d를 갖는 헤르페스 바이러스
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
CA3103374A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
KR101998793B1 (ko) * 2018-09-04 2019-07-10 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
AU2023319760A1 (en) * 2022-08-05 2025-02-13 Immvira Biopharmaceuticals Co., Limited Replication incompetent herpes simplex virus type 1 viral vaccine
WO2025119252A1 (en) * 2023-12-06 2025-06-12 Immvira Biopharmaceuticals Co., Limited Methods for detecting an anti-hsv antibody in a sample

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
GB9415320D0 (en) † 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
WO1998041873A1 (en) * 1997-03-14 1998-09-24 The University Court Of The University Of Glasgow Methods for identifying cell cycle regulators
CA2284611A1 (en) * 1997-03-27 1998-10-01 Richard B. Pyles Replication-competent herpes simplex viruses
AU8605598A (en) * 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6673602B1 (en) * 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
PT1212428E (pt) * 1999-08-31 2005-03-31 Gen Hospital Corp Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores
GB2375113B (en) * 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
EP1549339B1 (de) 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
GB2386895A (en) 2003-10-01
GB0203285D0 (en) 2002-03-27
WO2003068809A8 (en) 2004-09-23
GB2386895B (en) 2004-03-10
DE60304835D1 (de) 2006-06-01
US20110244576A1 (en) 2011-10-06
EP1474521B2 (de) 2014-02-26
US8778684B2 (en) 2014-07-15
JP2005532039A (ja) 2005-10-27
CA2475604C (en) 2012-01-03
AU2003245765B2 (en) 2007-11-08
JP4509572B2 (ja) 2010-07-21
DE60304835T2 (de) 2006-11-30
AU2003245765A1 (en) 2003-09-04
GB0303188D0 (en) 2003-03-19
WO2003068809A2 (en) 2003-08-21
US20050271620A1 (en) 2005-12-08
WO2003068809A3 (en) 2003-10-16
EP1474521A2 (de) 2004-11-10
US7943144B2 (en) 2011-05-17
DE60304835T3 (de) 2014-07-17
CA2475604A1 (en) 2003-08-21
EP1474521B1 (de) 2006-04-26

Similar Documents

Publication Publication Date Title
ATE324459T1 (de) Ein herpes simplex virus komplex
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
ATE466932T1 (de) Vermehrung von viren in zellkultur
UA108598C2 (xx) Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
WO2011130749A3 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO2003104411A3 (en) BIOARTIFICIAL LIVER SYSTEM
EP1767642A4 (de) Konstruktion einer den immunmodulatorischen faktor gm-csf in tumorzellen spezifisch exprimierenden onkolytischen adenovirus-rekombinanten sowie verwendungen davon
WO2005047524A3 (en) Compositions and methods for inducing cell dedifferentiation
EP1909849A4 (de) Verwendung von mutiertem herpes simplexvirus 2 für die krebstherapie
ATE295739T1 (de) ADENOVIRALE VEKTOREN BEINHALTEND EIN PROSTATA SPEZIFISCHES ANTIGEN (PSA) ßRESPONSE ELEMENTß
NO20080362L (no) CD19-antistoffer og deres anvendelser
WO2006099427A3 (en) Emissions tracking, such as vehicle emissions tracking, and associated systems and methods
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
RU96102402A (ru) Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
AU2003223089A1 (en) Compositions and methods for treating cancer with an oncolytic viral agent
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
SG149870A1 (en) Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
WO2003082330A1 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
WO2006119150A3 (en) Compositions and methods for targeting of viral vectors
TR200400184T2 (tr) Herbisidal bileşiklere tolerans veren DNA molekülleri
O'Nions et al. Deregulation of the cell cycle by the Epstein-Barr virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1474521

Country of ref document: EP